^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD1 inhibitor

    Related drugs:
    13h
    A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=423, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    15h
    P-RAD(+)TN-DCT: Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab)
    17h
    Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC (clinicaltrials.gov)
    P2, N=75, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Suspended
    Trial suspension
    |
    Keytruda (pembrolizumab) • Inlyta (axitinib)
    17h
    A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) (clinicaltrials.gov)
    P1, N=5, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=82 --> 5
    Trial completion • Enrollment change
    |
    Keytruda (pembrolizumab)
    19h
    Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Colorectal Cancer With High Microsatellite Instability or Mismatched Repair Deficiency in Japan. (PubMed, Value Health Reg Issues)
    Although outcomes varied depending on the PEM treatment duration and the medical cost setting after disease progression in the SoC group, PEM was suggested to be more cost-effective than SoC at the reference willingness-to-pay threshold of JPY15 million per QALY in Japan.
    Journal • HEOR • Microsatellite instability • Cost-effectiveness • MSI-H
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    19h
    CS1003-305: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=534, Active, not recruiting, CStone Pharmaceuticals | Trial completion date: Oct 2025 --> Sep 2026
    Trial completion date
    |
    Lenvima (lenvatinib) • nofazinlimab (CS1003)
    19h
    Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=67, Completed, Washington University School of Medicine | Trial completion date: Dec 2025 --> Jul 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • cisplatin
    20h
    KEYNOTE 811: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) (clinicaltrials.gov)
    P3, N=738, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    1d
    Tumor Imaging Heterogeneity Index-Inspired Insights into the Unveiling Tumor Microenvironment of Breast Cancer. (PubMed, Int J Mol Sci)
    The "immune+/replication+" showed sensitivity to pembrolizumab (OR = 10.192, p < 0.001) and veliparib/carboplatin (OR = 5.184, p = 0.006), while "immune-/replication-" responded poorly to pembrolizumab (OR = 0.086, p < 0.001). Additionally, "immune+/replication-" had the best distant recurrence-free survival (DRFS), whereas "immune-/replication+" had the worst (log-rank p = 6 × 10-4, HR = 5.45). By linking imaging heterogeneity directly to molecular subtypes and therapeutic response, this framework provides a robust, non-invasive surrogate for genomic profiling and a strategic tool for personalized neoadjuvant therapy selection.
    Journal • PARP Biomarker • PD(L)-1 Biomarker
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Keytruda (pembrolizumab) • carboplatin • veliparib (ABT-888)
    1d
    A Bidirectional EF1 Promoter System for Armoring CD19 CAR-T Cells with Secreted Anti-PD1 Antibodies. (PubMed, Int J Mol Sci)
    The sequences for the anti-PD1 modules were derived from the clinical antibody nivolumab...Critically, in a serial rechallenge assay designed to simulate chronic antigen exposure, both armored CAR-T cell groups showed markedly enhanced proliferation and persistence compared to conventional CAR-T cells, which failed to expand after repeated stimulation. Our findings validate the bidirectional EF1 promoter as an efficient system for generating multi-functional T cells and demonstrate that armoring CAR-T cells with secreted anti-PD1 antibodies is a potent strategy to enhance their persistence and anti-tumor efficacy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD19 (CD19 Molecule)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab)
    1d
    HYPERBOLIC: Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial (clinicaltrials.gov)
    P2, N=74, Not yet recruiting, Università Vita-Salute San Raffaele
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc)
    1d
    Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial (clinicaltrials.gov)
    P2, N=440, Not yet recruiting, Women's Hospital School Of Medicine Zhejiang University | Initiation date: Sep 2025 --> Jan 2026
    Trial initiation date
    |
    AiRuiKa (camrelizumab)